8-K 1 f8-k.htm 8-K Gemp_8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K  

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 6, 2019  

 

GEMPHIRE THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Delaware

 

001-37809

 

47-2389984

(State or other jurisdiction

of incorporation)

 

(Commission

File No.)

 

(IRS Employer

Identification No.)

 

P.O. Box 130235, Ann Arbor, MI 48113

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (734) 2451700

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

GEMP

Nasdaq

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

Item 5.07Submission of Matters to a Vote of Security Holders.

At the annual meeting of stockholders of Gemphire Therapeutics Inc. (the “Company”) held on December 6, 2019 (the “Annual Meeting”), stockholders of the Company voted as set forth below on the following proposals, each of which is described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 6, 2019.

At the Annual Meeting, 11,077,908 shares of common stock, or approximately 74.49% of the outstanding common stock of the Company entitled to vote, were represented by proxy or in person.

The final voting results for each matter submitted to a vote of the Company’s stockholders are as follows:

Proposal 1Approval of the Issuance of Company Common Stock in the Merger and Resulting Change of Control of the Company

The approval of the issuance of shares of common stock of the Company to stockholders of NeuroBo Pharmaceuticals, Inc (“NeuroBo”) pursuant to the terms of the Agreement and Plan of Merger and Reorganization, dated as of July 24, 2019, as amended on October 29, 2019, by and among the Company, GR Merger Sub Inc. and NeuroBo, and the change of control of the Company resulting from the merger under Nasdaq rules.

 

Votes For

 

Votes Against

 

Votes Abstain

Broker Non-Votes

6,897,514

 

57,459

 

16,532

4,106,403

 

Proposal 2Approval of the Amendment to the Gemphire Certificate of Incorporation to Effect the Reverse Stock Split

The approval of an amendment to the third amended and restated certificate of incorporation of the Company (the “Gemphire Certificate of Incorporation”) to effect a reverse stock split of the Company’s common stock, within a range, as determined by the Company’s board of directors, of one new share for every 15 to 25 shares outstanding (or any number in between).

 Votes For

 

Votes Against

 

Votes Abstain

10,864,721

 

190,116

 

23,071

 

Proposal 3Approval of the Amendment to the Gemphire Certificate of Incorporation to Effect the Corporate Name Change

The approval of an amendment to the Gemphire Certificate of Incorporation to change the corporate name of the Company from “Gemphire Therapeutics Inc.” to “NeuroBo Pharmaceuticals, Inc.”

 

 

 

 

 

 

Votes For

 

Votes Against

 

Votes Abstain

10,951,089

 

102,654

 

24,165

 

Proposal 4Approval of the Gemphire Therapeutics Inc. 2019 Equity Incentive Plan

The approval of the adoption of the Gemphire Therapeutics Inc. 2019 Equity Incentive Plan.

 

 

 

 

 

 

 

Votes For

 

Votes Against

 

Votes Abstain

Broker Non-Votes

5,349,274

 

1,256,849

 

365,382

4,106,403

 

Proposal 5—Election of Directors

The election of the two nominees for Class III directors named in the proxy statement/prospectus/information statement to the Company’s board of directors, each to serve a three-year term until the 2022 annual meeting of stockholders and until the election and qualification of his successor, or his earlier death, resignation or removal (provided that, if the merger is completed, the Company’s board of directors will be reconstituted as provided in the Merger Agreement).

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Class III Nominees

  

Votes For

  

Votes Withheld

 

Broker Non-Votes

 

Pedro Lichtinger

  

6,264,086

 

707,419

 

 

4,106,403

 

Andrew Sassine

  

5,926,732

 

1,044,773

 

 

4,106,403

  

 

Proposal 6—Ratification of Appointment of Independent Registered Public Accounting Firm

The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019 (provided, however, that it is likely that the combined company may decide to engage a new independent registered public accounting firm immediately or shortly after the merger is completed).

 

Votes For

 

Votes Against

 

Votes Abstain

Broker Non-Votes

10,996,599

 

51,421

 

29,888

0

 

In connection with the Annual Meeting, the Company also solicited proxies with respect to a proposal to adjourn the Annual Meeting, if necessary or appropriate, to solicit additional proxies if there were not sufficient votes to approve either Proposal 1, 2, 3 or 4 at the time of the Annual Meeting. Because the Company’s stockholders approved the adoption of each of Proposal 1, 2, 3 and 4, as noted above, the adjournment proposal was not brought forward for a vote at the Annual Meeting.

 

Item 8.01Other Events.

On December 6, 2019, the Company announced voting results relating to the Annual Meeting. A copy of the press release is attached hereto as Exhibit 99.1.

 

Item 9.01Financial Statements and Exhibits.

(d) Exhibits

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GEMPHIRE THERAPEUTICS INC.

 

 

 

 

Dated: December 6, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

By:

 

/s/ Dr. Steven Gullans 

 

 

 

 

 

 

Dr. Steven Gullans

 

 

 

 

 

 

President and Chief Executive Officer